



Published in final edited form as:

*J Gerontol A Biol Sci Med Sci.* 2005 October ; 60(10): 1339–1344.

## Association of Diastolic Dysfunction and Outcomes in Ambulatory Older Adults with Chronic Heart Failure

Ali Ahmed, MD, MPH

*Divisions of Gerontology and Geriatric Medicine, Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, Geriatric Heart Failure Clinic, and Center for Aging, University of Alabama at Birmingham, and Sections of Geriatrics and Geriatric Heart Failure Clinic, VA Medical Center, and Alabama Quality Assurance Foundation, Birmingham, Alabama*

### Abstract

**Background**—Studies of patients with heart failure and preserved systolic function report variable outcomes compared with those with impaired systolic function.

**Objective**—To study outcomes of diastolic (versus systolic) heart failure in older adults with chronic heart failure.

**Methods**—Patients were ambulatory chronic heart failure patients 65 years and older (N=3,984) who participated in the Digitalis Investigation Group trial. Of these, 3,405 had systolic heart failure (SHF) (ejection fraction  $\leq 45\%$ ) and 579 had diastolic heart failure (DHF) (ejection fraction  $>45\%$ ). Using a 1:1 match by age, sex and race, 571 DHF patients were matched with 571 SHF patients. Kaplan Meier survival analyses and multivariable Cox proportional hazard analyses were used to estimate the risk of various outcomes between the groups.

**Results**—During the 1,044 mean days of follow up, compared with 41% of SHF patients, 27% of DHF patients died ( $p < 0.001$ ). Presence of DHF was independently associated with a 27% decreased risk of all cause death (adjusted hazard ratio {HR} = 0.73; 95% confidence interval {CI} = 0.58 - 0.91) and a 32% reduction in risk of hospitalization due to heart failure (adjusted HR = 0.68; 95% CI = 0.52 - 0.88). There was no difference in overall hospitalization between the groups. However, compared with SHF patients, DHF patients were more likely to be hospitalized due to non-cardiovascular causes (adjusted HR = 1.38; 95% CI = 1.02 - 1.88).

**Conclusions**—Older adults with DHF had lower risk of all-cause mortality and heart failure related hospitalizations, but higher risk on non-cardiovascular hospitalization.

### Keywords

Diastolic heart failure; mortality; hospitalization; older adults

---

Heart failure with preserved left ventricular systolic function, also known as diastolic heart failure is relatively common among older adults.<sup>1-8</sup> Most studies of outcomes of diastolic heart failure in older adults involved hospitalized patients.<sup>1, 8-11</sup> These studies involve all-cause mortality and heart failure hospitalization and are limited by selection bias. Community based studies, most of which include patients of all age groups, are limited by their small sample size.<sup>4, 6, 7</sup> The purpose of this study was determine various outcomes in older adults with diastolic heart failure compared with a age-, sex-, and race-matched cohort with systolic heart failure.

---

**Contact information for corresponding author:** Ali Ahmed, MD, MPH, Division of Gerontology and Geriatric Medicine, Department of Medicine, School of Medicine, University of Alabama at Birmingham, 1530 3<sup>rd</sup> Ave South, CH-19, Ste-219, Birmingham AL 35294-2041; email: aahmed@uab.edu.

## METHODS

### Study Design

Digitalis Investigation Group (DIG) trial was a randomized controlled trial of patients with heart failure. The purpose of the DIG trial was to determine the effects of digoxin on mortality and hospitalizations in chronic systolic heart failure patients with normal sinus rhythm. The trial was conducted at 302 centers in the United States and Canada and details of the study design, baseline characteristics of the patients, and results are published elsewhere.<sup>12, 13</sup> The DIG dataset was obtained from the National Heart, Lung and Blood Institute of the National Institutes of Health. All patients signed informed consent forms and the protocol was approved by the Institutional Review Boards of all the participating centers. DIG trial enrolled 7,788 ambulatory patients with chronic heart failure. The Institutional Review Board of the University of Alabama at Birmingham approved the use of the dataset.

### Study Patients

In the original DIG trial, 7,788 heart failure patients were randomized to either digoxin or placebo group.<sup>5</sup> Of these, 6,800 had systolic heart failure and 988 had diastolic heart failure. Patients were recruited irrespective of their heart failure etiology or New York Heart Association (NYHA) functional class. Patients with non-sinus rhythm were excluded and all patients were encouraged to be on ACE inhibitors. For the present study, we excluded 3,804 patients younger than 65 years. Of the 3,984 patients in this study, 579 had diastolic heart failure and 3,405 had systolic heart failure. Of the 579 patients with diastolic heart failure, 571 were matched by age, sex, and race with 571 patients with systolic heart failure.

### Diagnosis of Heart Failure and Evaluation of Systolic Function

In the DIG trial, the diagnosis of heart failure was established based on current or past clinical symptoms or signs or radiographic evidence of pulmonary congestion. Left ventricular systolic function was evaluated by two-dimensional echocardiography, radionuclide ventriculography and contrast left ventriculography. In the original trial, 6,800 patients with left ventricular ejection fraction  $\leq 45\%$  (systolic heart failure) and were randomized in the main trial, and 988 patients with left ventricular ejection fraction  $>45\%$  (preserved systolic function or “probable” diastolic heart failure)<sup>14</sup> were randomized in the ancillary trial. For the purpose of this study, we used the same ejection fraction cutoff to define systolic and diastolic heart failure.

### Study Outcomes

Patients in the DIG trial were followed for a mean of 37 months, with range from 28 to 58 months.<sup>13</sup> The primary outcome of the main DIG trial was all-cause mortality. For the purpose of this study, we studied all-cause death, death due to heart failure, heart failure hospitalization, combined end point of heart failure hospitalization or all-cause mortality, all-cause hospitalization, and hospitalizations due to cardiovascular and non-cardiovascular causes.

### Statistical Analysis

Baseline characteristics of 579 diastolic heart failure and 3,405 systolic heart failure patients were compared at first. Then, we compared the baseline characteristics of 571 diastolic heart failure patients with 571 age, sex, and race-matched systolic heart failure patients. Pearson Chi-square tests and Student's *t* tests were used as appropriate to test for statistical significance.

Then, we used Kaplan-Meier survival analyses to compare various outcomes between the two groups and tested statistical significance using log rank *t* test. Bivariate and multivariable Cox proportional hazards models were used to compare various outcomes between the two groups of heart failure patients. Covariates used in the multivariable models included duration and

etiology of heart failure, comorbidities (myocardial infarction, angina, hypertension, diabetes, and chronic kidney disease (defined by estimated glomerular filtration rate of 60 ml/min/1.73m<sup>2</sup> “body surface area”), medications (digoxin, non-potassium sparing diuretics, and angiotensin-converting enzyme inhibitors), New York Heart Association functional class, clinical features vital signs (heart rate, systolic and diastolic blood pressure), and signs of heart failure (jugular venous distention, third heart sound, pulmonary râles, lower extremity edema, and pulmonary congestion by chest x-ray). All statistical tests were evaluated using a two-tailed 95% confidence level. Analyses were performed using SPSS for Windows (Release 12).  
15

## RESULTS

### Patient Characteristics

In the pre-match cohort, older adults with heart failure and diastolic heart failure were more likely to be older and female. In the matched cohort, patients had a mean ( $\pm$ SD) age of 72.6 ( $\pm$ 5.6) years, 42.7% female and 11.2% were non-whites (Table 1). Patients with diastolic heart failure were more likely to have hypertension and hypertensive cardiomyopathy, and less likely to have a history of acute myocardial infarction and ischemic cardiomyopathy. They were also less likely to have chronic kidney disease. Diastolic heart failure patients were more likely to present with lower extremity edema and less likely to have a third heart sound, jugular venous distention, or pulmonary congestion by chest x-ray. However, there were no significant differences in the prevalence of dyspnea and activity limitations between the groups.

### Mortality due to All Causes and Worsening Heart Failure

Three hundred eighty six patients (33.8%) died from all causes during the study. Compared with 41.0% (234/571) systolic heart failure patients, 26.6% (152/571) diastolic heart failure patients died during the study ( $p < 0.001$ ). The Kaplan Meier survival curves for all-cause mortality are displayed in Figure 1 (a). Mean survival in diastolic heart failure patients was over 6 months longer in patients with diastolic heart failure (mean survival of 1,426 days compared with 1,230 days for systolic heart failure patients; log rank test  $p < 0.001$ ). Compared with systolic heart failure patients, those with diastolic heart failure had a 41% lower risk of death from any cause (unadjusted hazard ratio {HR} = 0.59; 95% confidence interval {CI} = 0.48 - 0.72). After adjustment for covariates, presence of diastolic heart failure was independently associated with a significant 27% lower risk of death (adjusted HR = 0.73; 95% CI = 0.58 - 0.91).

One hundred twenty one patients (10.6%) died due to worsening heart failure during the study. Compared with 14.2% (81/571) deaths in systolic heart failure patients, 7.0% (40/571) diastolic heart failure patients died from worsening heart failure during the study ( $p < 0.001$ ). The Kaplan Meier survival curves for heart failure related deaths between the groups are displayed in Figure 1 (b). Diastolic heart failure patients had 114 days of longer mean survival free of heart failure related death (1,650 vs. 1,536 days for systolic heart failure patients;  $p < 0.001$ ). Compared with systolic heart failure patients, those with diastolic heart failure had a 46% lower risk of death from worsening heart failure (adjusted HR = 0.73; 95% CI = 0.58 - 0.91).

### Hospitalizations

Seven hundred sixty nine (67.3%) were hospitalized due to all causes during the study. There were no differences in the overall hospitalization between the groups. Hospitalizations due to worsening heart failure was significantly lower in diastolic heart failure patients (20.0% vs. 31.3% in systolic heart failure patients;  $p < 0.001$ ). The Kaplan Meier survival curves for all-cause and heart failure hospitalizations are displayed in Figures 2 (a) and (b) respectively. Diastolic heart failure was associated with a 28% independent reduction in hospitalization due

to worsening heart failure (adjusted HR = 0.68; 95% CI = 0.52 - 0.88). The risk of combined end point of hospitalization due to worsening heart failure or all-cause death was lower in older adults with diastolic heart failure (Table 2). While the risk of hospitalization due to cardiovascular causes were lower (adjusted HR = 0.83; 95% CI = 0.69 - 0.99) in diastolic heart failure patients, they were more likely to be hospitalized due to non-cardiovascular causes (Figure 3 a and b, Table 2). There were no differences between the two groups in risks of hospitalization due to acute myocardial infarction, unstable angina, supraventricular arrhythmias, coronary revascularization or stroke.

## DISCUSSION

The results of this study are important for several reasons. This is the first study that reports various outcomes in community dwelling older adults with diastolic heart failure compared with systolic heart failure. The results of this study demonstrate that compared with systolic heart failure patients, diastolic heart failure patients had overall lower risks of death. However, there were no differences in overall hospitalizations between the groups. Even though, diastolic heart failure patients were less likely to have hospitalizations due to cardiovascular causes, they had higher risk for non-cardiovascular hospitalizations suggesting significant burden of morbidity in these patients.

In a recent review of literature, Hogg et al. identified 12 studies of hospitalized diastolic heart failure patients published since January 2000.<sup>9</sup> While some of these studies were restricted to patients 65 years and older, as most hospitalized heart failure patients are older adults, all of these studies involved older adults.<sup>1, 11, 16-25</sup> Nine of these studies reported mortality (all-cause) as an outcome.<sup>1, 16, 18-21, 23-25</sup> Results from seven of these studies suggest that older adults with diastolic heart failure have better survival compared with systolic heart failure patients.<sup>1, 16, 18-20, 23, 24</sup> In one study, mortality rates between diastolic and systolic heart failure patients were similar.<sup>21</sup> Several other previous studies have also observed no difference in mortality between patients with systolic and diastolic heart failure.<sup>26-28</sup> In one study of hospitalized veterans, presence of diastolic heart failure was associated with increased risk of death.<sup>25</sup> However, in that study heart failure patients were identified using an electronic search of computerized medical record for administrative coding of heart failure as the primary discharge diagnosis. In one study of older adults with heart failure associated with prior myocardial infarction living in long-term care facilities, patients with impaired systolic function had higher mortality rate than those with preserved systolic function.<sup>29</sup>

Most population based studies of diastolic heart failure suffer from small numbers of diastolic heart failure patients.<sup>6, 7, 30-32</sup> Most of these studies are also not restricted to patients 65 years and older. In the Cardiovascular Health Study that involved 5,532 community-dwelling persons 65 years and older, 249 (4.9%) had heart failure.<sup>6</sup> One hundred seventy (63%) of them diastolic heart failure based on left ventricular ejection fraction >55%. Thirty nine patients (15%) had ejection fraction between 45 and 54% and 60 (22%) had systolic heart failure (ejection fraction <45%). In that study, respective annual mortality rates for diastolic, borderline and systolic heart failure patients were 8.7%, 11.5% and 15.4%.<sup>6</sup> Compared with healthy cohorts with normal systolic function, presence of diastolic, borderline and systolic heart failure were independently associated with respectively 48%, 140% and 88% higher risk of death from any cause.<sup>6</sup> Several other community based studies did not observe any mortality differences between diastolic and systolic heart failure.<sup>6, 7, 30</sup> In all these studies, the number of diastolic heart failure patients was relatively low: 20 in Helsinki Aging Study,<sup>30</sup> 37 in the Framingham Heart Study,<sup>7</sup> and 59 in the Mayo Clinic Olmsted County study.<sup>31</sup> To our knowledge, the current study is the first to demonstrate significant lower risk of all-cause mortality and mortality due to worsening heart failure in a large cohort of ambulatory older adults with diastolic heart failure. Using the Veterans Administration Cooperative Study trial dataset, Cohn

et al. demonstrated a similar survival benefit associated with diastolic heart failure (ejection fraction  $\geq 45\%$ ).<sup>33</sup> However, patients in that study were younger (mean age 60 years).

Data on hospitalization among patients with diastolic heart failure is relatively scarce in the literature. In the Olmsted County study, of 51% (30/59) patients with diastolic heart failure had one hospitalization due to heart failure and 25% (15/59) had 2 or more hospitalizations due to heart failure. On the other hand, in that study 41% (32/78) patients with systolic heart failure had one and 49% (38/78) had 2 or more hospitalizations due to heart failure.<sup>31</sup> There is no reports on hospitalization in patients with diastolic heart failure from the Framingham Heart Study or Cardiovascular Heart Study.<sup>6, 7</sup> In hospitalized heart failure patients, the risk of heart failure-related hospitalization has been variously reported to be lower than<sup>1</sup> or similar to that of systolic heart failure.<sup>18, 23</sup> Several of these studies reported all-cause hospitalization and did not find any difference between the two groups.<sup>16-18</sup> We too observed a similar all-cause hospitalization between patients with systolic and diastolic heart failure. However, we noted that while hospitalizations due to all cardiovascular causes were lower in diastolic heart failure patients, except for those due to worsening heart failure, there were no differences between the two groups in terms of hospitalizations due to other major cardiovascular reasons. On the other hand, risk of hospitalizations due to non-cardiovascular causes was higher in patients with diastolic heart failure.

One of the limitations of our study is patients in our study were in normal sinus rhythm. Atrial fibrillation is common in older adults with heart failure and is associated with poor outcomes.<sup>34, 35</sup> In addition, we did not exclude patients with valvular heart disease. Only 56 of the 3,984 patients 65 years and older (1.4%) patients had valvular heart disease identified as primary cause of heart failure. A subgroup analysis excluding these patients demonstrated similar results on key outcomes.

In conclusion, the results of our study suggest that among community dwelling older adults compared with an age-sex-race matched cohort of systolic heart failure patients those with diastolic heart failure have better survival. However, despite a lower risk for hospitalization due to heart failure, hospitalizations due to other cardiovascular causes were similar and those due to non-cardiovascular hospitalizations were higher. With the population aging, this might impose burden on older adults and the health care system. Future studies should examine if more aggressive evaluation and management of comorbidities such as coronary artery disease or hypertension would reduce this burden.

## Acknowledgement / Disclaimer

“The Digitalis Investigation Group (DIG) study was conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the Digitalis Investigation Group (DIG) Investigators. This manuscript has been reviewed by NHLBI for scientific content and consistency of data interpretation with previous The Digitalis Investigation Group (DIG) publications and significant comments have been incorporated prior to submission for publication.”

**Funding/Support:** Dr. Ahmed is supported by a National Institutes of Health Research Career Development Award 1-K23-AG19211-01

**Grant support:** Dr. Ahmed is supported by a National Institute on Aging Research Career Development Award 1-K23-AG19211-01

## REFERENCES


1. Ahmed A, Roseman JM, Duxbury AS, et al. Correlates and outcomes of preserved left ventricular systolic function among older adults hospitalized with heart failure. *Am Heart J* 2002;144:365–372. [PubMed: 12177658]




2. Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. *J Am Geriatr Soc* 1997;45:968–974. [PubMed: 9256850]
3. Aronow WS, Ahn C, Kronzon I. Comparison of incidences of congestive heart failure in older African-Americans, Hispanics, and whites. *Am J Cardiol* 1999;84:611–612. A619. [PubMed: 10482169]
4. Senni M, Redfield MM. Heart failure with preserved systolic function. A different natural history? *J Am Coll Cardiol* 2001;38:1277–1282. [PubMed: 11691495]
5. Pernenkil R, Vinson JM, Shah AS, et al. Course and prognosis in patients > or = 70 years of age with congestive heart failure and normal versus abnormal left ventricular ejection fraction. *Am J Cardiol* 1997;79:216–219. [PubMed: 9193031]
6. Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. *Ann Intern Med* 2002;137:631–639. [PubMed: 12379062]
7. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. *J Am Coll Cardiol* 1999;33:1948–1955. [PubMed: 10362198]
8. Lenzen MJ, Scholte Op, Reimer WJ, Boersma E, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. *Eur Heart J* 2004;25:1214–1220. [PubMed: 15246639]
9. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. *J Am Coll Cardiol* 2004;43:317–327. [PubMed: 15013109]
10. Ibrahim SA, Burant CJ, Kent Kwoh C. Elderly hospitalized patients with diastolic heart failure: lack of gender and ethnic differences in 18-month mortality rates. *J Gerontol A Biol Sci Med Sci* 2003;58:56–59. [PubMed: 12560412]
11. Masoudi FA, Havranek EP, Smith G, et al. Gender, age, and heart failure with preserved left ventricular systolic function. *J Am Coll Cardiol* 2003;41:217–223. [PubMed: 12535812]
12. Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. *Control Clin Trials* 1996;17:77–97. [PubMed: 8721804]
13. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. *N Engl J Med* 1997;336:525–533. [PubMed: 9036306]
14. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. *Circulation* 2000;101:2118–2121. [PubMed: 10790356]
15. SPSS for Windows, Rel. 12.0.2. SPSS Inc.; Chicago, IL: 2004. Version
16. Philbin EF, Rocco TA Jr, Lindenmuth NW, et al. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. *Am J Med* 2000;109:605–613. [PubMed: 11099679]
17. Malki Q, Sharma ND, Afzal A, et al. Clinical presentation, hospital length of stay, and readmission rate in patients with heart failure with preserved and decreased left ventricular systolic function. *Clin Cardiol* 2002;25:149–152. [PubMed: 12000071]
18. Dauterman KW, Go AS, Rowell R, et al. Congestive heart failure with preserved systolic function in a statewide sample of community hospitals. *J Card Fail* 2001;7:221–228. [PubMed: 11561221]
19. Cohen-Solal A, Desnos M, Delahaye F, et al. The Myocardial Pathology and Heart Failure Working Group of the French Society of Cardiology; the National College of General Hospital Cardiologists and the French Geriatrics Society. A national survey of heart failure in French hospitals. *Eur Heart J* 2000;21:763–769. [PubMed: 10739732]
20. Varela-Roman A, Gonzalez-Juanatey JR, Basante P, et al. Clinical characteristics and prognosis of hospitalised inpatients with heart failure and preserved or reduced left ventricular ejection fraction. *Heart* 2002;88:249–254. [PubMed: 12181216]
21. Tsutsui H, Tsuchihashi M, Takeshita A. Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. *Am J Cardiol* 2001;88:530–533. [PubMed: 11524063]

22. Thomas JT, Kelly RF, Thomas SJ, et al. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. *Am J Med* 2002;112:437–445. [PubMed: 11959053]
23. Smith GL, Masoudi FA, Vaccarino V, et al. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. *J Am Coll Cardiol* 2003;41:1510–1518. [PubMed: 12742291]
24. Gustafsson F, Torp-Pedersen C, Brendorp B, et al. Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. *Eur Heart J* 2003;24:863–870. [PubMed: 12727154]
25. Varadarajan P, Pai RG. Prognosis of congestive heart failure in patients with normal versus reduced ejection fractions: results from a cohort of 2,258 hospitalized patients. *J Card Fail* 2003;9:107–112. [PubMed: 12751131]
26. Taffet GE, Teasdale TA, Bleyer AJ, et al. Survival of elderly men with congestive heart failure. *Age Ageing* 1992;21:49–55. [PubMed: 1553860]
27. McDermott MM, Feinglass J, Lee PI, et al. Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. *Am Heart J* 1997;134:728–736. [PubMed: 9351741]
28. McAlister FA, Teo KK, Taher M, et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. *Am Heart J* 1999;138:87–94. [PubMed: 10385769]
29. Aronow WS, Ahn C, Kronzon I. Prognosis of congestive heart failure after prior myocardial infarction in older men and women with abnormal versus normal left ventricular ejection fraction. *Am J Cardiol* 2000;85:1382–1384. [PubMed: 10831962]
30. Kupari M, Lindroos M, Iivanainen AM, et al. Congestive heart failure in old age: prevalence, mechanisms and 4-year prognosis in the Helsinki Ageing Study. *J Intern Med* 1997;241:387–394. [PubMed: 9183306]
31. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. *Circulation* 1998;98:2282–2289. [PubMed: 9826315]
32. Cortina A, Reguero J, Segovia E, et al. Prevalence of heart failure in Asturias (a region in the north of Spain). *Am J Cardiol* 2001;87:1417–1419. [PubMed: 11397369]
33. Cohn JN, Johnson G, Veterans Administration Cooperative Study Group. Heart failure with normal ejection fraction. The V-HeFT Study. *Circulation* 1990;81:III48–53. [PubMed: 2404638]
34. Ahmed A, Thornton P, Perry GJ, et al. Impact of atrial fibrillation on mortality and readmission in older adults hospitalized with heart failure. *Eur J Heart Fail* 2004;6:421–426. [PubMed: 15182766]
35. Aronow WS, Ahn C, Kronzon I. Prognosis of congestive heart failure after prior myocardial infarction in older persons with atrial fibrillation versus sinus rhythm. *Am J Cardiol* 2001;87:224–225. A228–229. [PubMed: 11152847]

(a)




(b)




**Figure 1.** Kaplan-Meier plots for (a) all cause mortality and (b) heart failure related mortality for heart failure patients with systolic vs. diastolic dysfunction.



(a)




(b)




**Figure 2.** Kaplan-Meier plots for hospitalization due to (a) all cause and (b) worsening heart failure in patients with systolic vs. diastolic dysfunction.

(a)



(b)



**Figure 3.** Kaplan-Meier plots demonstrating hospitalization due to (a) cardiovascular and (b) non-cardiovascular causes among chronic heart failure patients by left ventricular systolic function

**Table 1**  
**Baseline patient characteristics by left ventricular systolic function after age-sex-race matching**

|  | Systolic heart failure N = 571 | Diastolic heart failure N = 571 | P value |
|--|--------------------------------|---------------------------------|---------|
| Age (years), mean ( $\pm$ SD)                            | 72.6 ( $\pm$ 5.6)              | 72.6 ( $\pm$ 5.6)               | >0.999  |
| Female   | 244 (42.7%)                    | 244 (42.7%)                     | >0.999  |
| Non-white  | 64 (11.2%)                     | 64 (11.2%)                      | >0.999  |
| Duration of heart failure (months), mean ( $\pm$ SD)     | 28.0 ( $\pm$ 32.9)             | 25.1 ( $\pm$ 29.3)              | 0.116   |
| Primary cause of heart failure                           |                                |                                 |         |
| Ischemic   | 412 (72.2%)                    | 345 (60.4%)                     |         |
| Hypertensive   | 62 (10.9%)                     | 158 (27.7%)                     | <0.001  |
| Idiopathic   | 63 (11.0%)                     | 50 (8.8%)                       |         |
| Others   | 34 (6%)                        | 18 (3.2%)                       |         |
| Comorbid conditions                                      |                                |                                 |         |
| Prior myocardial infarction                              | 380 (66.5%)                    | 292 (51.1%)                     | <0.001  |
| Current angina   | 151 (26.4%)                    | 181 (31.7%)                     | 0.051   |
| Hypertension   | 288 (50.4%)                    | 357 (62.5%)                     | <0.001  |
| Diabetes   | 167 (29.2%)                    | 160 (28.1%)                     | 0.660   |
| Chronic kidney disease                                   | 360 (63.0%)                    | 327 (57.3%)                     | 0.046   |
| Medications  |                                |                                 |         |
| Pre-trial digoxin use                                    | 245 (42.9%)                    | 193 (33.8%)                     | 0.002   |
| Digoxin use  | 288 (50.4%)                    | 283 (49.6%)                     | 0.767   |
| ACE inhibitors   | 538 (94.2%)                    | 492 (86.2%)                     | <0.001  |
| Non-potassium sparing diuretics                          | 461 (80.7%)                    | 440 (77.1%)                     | 0.128   |
| Potassium sparing diuretics                              | 43 (8.9%)                      | 50 (8.8%)                       | 0.449   |
| Potassium supplement                                     | 157 (27.5%)                    | 157 (27.5%)                     | >0.999  |
| Symptoms and signs of heart failure (current)            |                                |                                 |         |
| Dyspnea at rest  | 396 (69.4%)                    | 389 (68.1%)                     | 0.655   |
| Dyspnea on exertion                                      | 544 (95.3%)                    | 550 (96.3%)                     | 0.376   |
| Activity limitation                                      | 533 (93.3%)                    | 521 (91.2%)                     | 0.183   |
| Jugular venous distension                                | 315 (55.2%)                    | 265 (46.4%)                     | 0.003   |
| Third heart sound  | 269 (47.1%)                    | 166 (29.1%)                     | <0.001  |
| Pulmonary rales  | 439 (76.9%)                    | 421 (73.7%)                     | 0.217   |
| Lower extremity edema                                    | 300 (52.5%)                    | 335 (58.7%)                     | 0.037   |
| NYHA functional class                                    |                                |                                 |         |
| I  | 58 (10.2%)                     | 102 (17.9%)                     |         |
| II   | 299 (52.4%)                    | 321 (56.2%)                     | <0.001  |
| III  | 197 (34.5%)                    | 138 (24.2%)                     |         |
| IV   | 17 (3.0%)                      | 10 (1.8%)                       |         |
| Heart rate (/minute), mean ( $\pm$ SD)                   | 78.4 ( $\pm$ 12.5)             | 75.2 ( $\pm$ 11.6)              | <0.001  |
| Blood pressure (mm Hg), mean ( $\pm$ SD)                 |                                |                                 |         |
| Systolic   | 128.5 ( $\pm$ 20.1)            | 139.9 ( $\pm$ 20.7)             | <0.001  |
| Diastolic  | 74.0 ( $\pm$ 11.6)             | 76.5 ( $\pm$ 11.0)              | <0.001  |
| Chest radiograph findings                                |                                |                                 |         |
| Pulmonary congestion                                     | 401 (70.2%)                    | 353 (61.8%)                     | <0.001  |
| Laboratory data, mean ( $\pm$ SD)                        |                                |                                 |         |
| Serum creatinine (mg/dL)                                 | 1.34 ( $\pm$ 0.40)             | 1.28 ( $\pm$ 0.39)              | 0.010   |
| Serum potassium (mEq/L)                                  | 4.37 ( $\pm$ 0.47)             | 4.35 ( $\pm$ 0.41)              | 0.339   |
| Left ventricular ejection fraction (%), mean ( $\pm$ SD) | 29.3 ( $\pm$ 9.0)              | 55.7 ( $\pm$ 8.1)               | <0.001  |

**Table 2**

Crude and adjusted hazard ratios (95% confidence intervals) for various outcomes for older adults with systolic vs. diastolic heart failure

|   | Events (systolic / diastolic (p value)) | Unadjusted         | Adjusted <sup>*</sup> |
|---|---|--------------------|-----------------------|
| Mortality due to all causes                                 | 41.0% / 26.6% (< 0.001)                 | 0.59 (0.48 - 0.72) | 0.73 (0.58 - 0.91)    |
| Mortality due to heart failure                              | 14.2% / 7.0% (< 0.001)                  | 0.45 (0.31 - 0.65) | 0.54 (0.36 - 0.82)    |
| Hospitalization due to all causes                           | 66.9% / 67.8% (0.752)                   | 0.91 (0.79 - 1.05) | 0.97 (0.83 - 1.14)    |
| Hospitalization due to heart failure                        | 31.3% / 20.0% (< 0.001)                 | 0.55 (0.44 - 0.70) | 0.68 (0.52 - 0.88)    |
| Hospitalization due to cardiovascular causes                | 52.0% / 46.6% (< 0.067)                 | 0.78 (0.66 - 0.91) | 0.83 (0.69 - 0.99)    |
| Hospitalization due to non-cardiovascular causes            | 14.7% / 21.0% (0.005)                   | 1.32 (1.00 - 1.78) | 1.38 (1.02 - 1.88)    |
| Hospitalization due to heart failure or all-cause mortality | 55.0% / 38.0% (< 0.001)                 | 0.59 (0.50 - 0.71) | 0.72 (0.60 - 0.88)    |

\* Adjusted for duration and etiology of heart failure, history of myocardial infarction, angina, hypertension, diabetes mellitus, and chronic kidney disease, use of digoxin, non-potassium sparing diuretics, and angiotensin-converting enzyme inhibitors, New York Heart Association functional class, heart rate, systolic and diastolic blood pressure, jugular venous distention, third heart sound, pulmonary râles, lower extremity edema, and pulmonary congestion by chest x-ray.